Evidence map›Paper›PMID 36652559›Full record

ArticleJournal of hepato-biliary-pancreatic sciences2023

Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients.

Minako Nagai, Michael J Wright, Ding Ding, Elizabeth D Thompson, Ammar A Javed, Matthew J Weiss, Ralph H Hruban, Jun Yu, Richard A Burkhart, Jin He and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepato-biliary-pancreatic sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Minako NagaiDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2102-1276
Michael J WrightDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ding DingDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Elizabeth D ThompsonDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ammar A JavedDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Matthew J WeissDepartment of Hepatobiliary Surgery, Pancreas, Oncology, Northwell Health Cancer Institute, New Hyde Park, New York, USA.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jun YuDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Richard A BurkhartDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-1087-0870
Jin HeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
John L CameronDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Christopher L WolfgangDepartment of Surgery, New York University Grossman School of Medicine and NYU-Langone Medical Center, New York, New York, USA.
William R BurnsDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · USNorthwell Health · USNYU Langone Health · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
NCI NIH HHS P50 CA062924
6 · The paper itself

Abstract

backgroundPatients with pancreatic ductal adenocarcinoma (PDAC) and liver metastasis are treated with palliative chemotherapy, whereas similar patients with metastatic colorectal cancer are considered for aggressive surgery.

methodsUsing an institutional database, PDAC patients undergoing liver resection for isolated metastasis were identified. Their overall survival (OS), treatment factors, and clinicopathological variables associated with survival were also evaluated.

resultsForty-seven patients underwent curative-intent surgery for metastatic PDAC to the liver between 2000 and 2019. Median OS was 21.9 months from diagnosis. Fourteen patients underwent unplanned resection of radiographically occult liver metastasis during pancreatectomy with median OS of 8.7 months. On the other hand, 29 patients received systemic chemotherapy followed by planned resection; this cohort had the most favorable prognosis following aggressive surgery with median OS being 38.1 months from diagnosis and 24.1 months from surgery. Preoperative chemotherapy (HR = 7.1; p = .002) and moderate to well differentiation of the primary tumor (HR = 3.7; p = .003) were associated with prolonged survival in multivariate analysis, whereas lymph node metastases, response to preoperative therapy, number of liver metastasis, and extent of liver surgery were not.

conclusionsIn select patients with PDAC and isolated liver metastasis, curative-intent surgery can result in meaningful survival. This aggressive approach seems most beneficial in patients following induction chemotherapy.

Indexed as

Carcinoma, Pancreatic DuctalLiver NeoplasmsPancreatic NeoplasmsHumansPancreatectomyPrognosisRetrospective StudiesSurvival Ratechemotherapyisolated liver metastasisoligometastatic pancreatic cancerresection

Identifiers

PMID36652559
PMCPMC10548446
OpenAlexW4317254378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.